[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:galactosidase-alpha":3},{"name":4,"total":5,"recruiting":5,"trials":6},"GALACTOSIDASE, ALPHA",5,[7,15,22,28,34],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06904261","A Study of Migalastat in Pediatric Subjects (2 to \u003C12 Yrs) With Fabry Disease and Amenable GLA Variants",[11],"Phase 3","RECRUITING","2026-08-26T02:18:35.425468Z","2026-05-05T02:43:29.077075Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06858397","A proof-of Concept Study to Assess Safety and Tolerability of HM15421\u002FGC1134A in Patients With Fabry Disease",[19],"Phase 1\u002FPhase 2","2026-08-26T02:17:38.215063Z","2026-05-05T02:43:29.042330Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06270316","Safety, PK\u002FPD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease",[19],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:28.317681Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06906367","A Study of Patients With Fabry Disease (US Specific)",[],"2026-08-26T02:18:27.904411Z","2026-05-13T02:55:06.590359Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT00196742","Fabry Disease Registry & Pregnancy Sub-registry",[],"2026-08-26T02:18:21.216897Z","2026-05-13T02:55:06.032092Z"]